Patents Assigned to LYSENTECH
  • Composition and method for increasing production of bacteriophage using reactive oxygen species
    Patent number: 11898171
    Abstract: Provided is a method and composition using ROS to increase the production of bacteriophage. According to the subject matter, a production amount of bacteriophage is increased several times in the presence of the sublethal concentration of ROS for host bacteria. Therefore, the method and composition of the subject matter can be useful for producing bacteriophage, which is used as an alternative to antibiotics that cause a serious resistance problem.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: February 13, 2024
    Assignee: LYSENTECH
    Inventors: Heejoon Myung, Yunyeol Jo
  • Polypeptide, fusion polypeptide, and antibiotic against gram-negative bacteria comprising same
    Patent number: 11807881
    Abstract: Provided are a novel polypeptide, a fusion polypeptide comprising the polypeptide, and a use thereof as an antibiotic. More specifically, provided are a novel polypeptide derived from a bacteriophage, a novel fusion polypeptide comprising cecropin A, and an antibiotic against Gram-negative bacteria comprising the polypeptide and/or the fusion polypeptide.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: November 7, 2023
    Assignee: LYSENTECH CO., LTD.
    Inventors: Heejoon Myung, Min Soo Kim, Hye-Won Hong, Jione Pyeon, Jaeyeon Jang
  • ONCOLYTIC T7 BACTERIOPHAGE HAVING CYTOKINE GENE AND DISPLAYING HOMING PEPTIDE ON CAPSID AND ITS USE FOR TREATING CANCER
    Publication number: 20210009963
    Abstract: Provided is an oncolytic recombinant bacteriophage T7 expressing a cytokine in eukaryotic cells and displaying on its capsid a tumor specific homing peptide, thus inducing direct lysis of target tumor cells and immunological response to the phage leading to the effective anticancer effect. The phage naturally infecting bacteria, not human beings, provides a great advantage for gene manipulation and production for the development of anticancer agents.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 14, 2021
    Applicant: LYSENTECH
    Inventors: Heejoon MYUNG, Yoonjung HWANG